TrialPath
Recruiting

A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis

NCT07276581 · AstraZeneca
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Multicentre, Parallel-group, Phase II, Randomised, Double-blind, 4 Arm Study to Evaluate Efficacy and Safety of AZD1163 in Participants With Moderately-to-Severely Active Rheumatoid Arthritis (LaunchPAD-RA)
About this study
AZD1163 is a novel bispecific antibody that inhibits the activity of extracellular peptidyl arginine deiminase 2 (PAD2) and peptidyl arginine deiminase 4 (PAD4) enzymes, which are responsible for protein citrullination. In RA, citrullinated proteins lead to the production of pathogenic anti-citrullinated peptide antibodies (ACPA). This is a Phase II, randomised, double-blind, multicentre, 4 arm placebo-controlled study designed to evaluate the efficacy and safety of AZD1163 in ACPA + adults with moderate-to-severely active RA on standard of care (SoC) (conventional synthetic disease-modifying antirheumatic drugs \[csDMARDs\] or tumour necrosis factor inhibitor \[TNFi\] +/- csDMARD). The study will have a screening period followed by a randomisation period wherein approximately 320 participants will be randomised in a 1:1:1:1 ratio to receive study intervention. Participants will receive subcutaneous (SC) injection of one of three different doses of AZD1163 or placebo, along with SoC until Week 24 followed by a safety follow-up (FU) period of 28 weeks.
Eligibility criteria
* Inclusion * Diagnosed with adult-onset RA as defined by the 2010 ACR/EULAR classification criteria for at least 12 weeks prior to screening. * Moderately-to-severely active RA as defined by: a. \>= 6 swollen joints on 66SJC and \>= 6 tender joints on 68TJC; b. CRP \> upper limit of normal. * Have a positive ACPA at screening. * A history of inadequate response, or loss of response, or intolerance to: a. at least one csDMARD treatment, AND/OR b. At least one and at most 2 TNFi. * A history of at least 12 weeks treatment and \>= 4 weeks stable on a csDMARD and/or SC TNFi prior to the day of randomisation. * Exclusion * History or evidence of an alternate autoimmune or other condition that could confound the diagnosis of RA. Participants with RA and secondary Sjogren's disease are eligible. * Have received or planning to receive any biologic DMARDs (except for TNFi) or targeted synthetic DMARDs.
Study design
Enrollment target: 320 participants
Allocation: randomized
Masking: quadruple
Age groups: adult, older_adult
Timeline
Starts: 2025-12-15
Estimated completion: 2028-08-18
Last updated: 2026-11-20
Interventions
Drug: AZD1163Other: Placebo
Primary outcomes
  • • Change From Baseline in Disease Activity Score-C-Reactive Protein (DAS28-CRP) at Week 12 (Week 12)
Sponsor
AstraZeneca · industry
Contacts & investigators
ContactAstraZeneca Clinical Study Information Center · contact · information.center@astrazeneca.com · 1-877-240-9479
All locations (147)
Research SiteRecruiting
Glendale, Arizona, United States
Research SiteWithdrawn
Prescott Valley, Arizona, United States
Research SiteRecruiting
Tucson, Arizona, United States
Research SiteRecruiting
La Jolla, California, United States
Research SiteWithdrawn
San Dimas, California, United States
Research SiteRecruiting
San Leandro, California, United States
Research SiteRecruiting
Aurora, Colorado, United States
Research SiteWithdrawn
Boynton Beach, Florida, United States
Research SiteWithdrawn
Jacksonville, Florida, United States
Research SiteSuspended
South Miami, Florida, United States
Research SiteWithdrawn
Tampa, Florida, United States
Research SiteRecruiting
Winter Haven, Florida, United States
Research SiteRecruiting
Marietta, Georgia, United States
Research SiteRecruiting
Skokie, Illinois, United States
Research SiteRecruiting
Willowbrook, Illinois, United States
Research SiteRecruiting
Lake Charles, Louisiana, United States
Research SiteRecruiting
Baltimore, Maryland, United States
Research SiteRecruiting
Rockville, Maryland, United States
Research SiteRecruiting
New Bedford, Massachusetts, United States
Research SiteRecruiting
Kansas City, Missouri, United States
Research SiteRecruiting
St Louis, Missouri, United States
Research SiteRecruiting
Henderson, Nevada, United States
Research SiteRecruiting
Myrtle Beach, South Carolina, United States
Research SiteRecruiting
Austin, Texas, United States
Research SiteRecruiting
Baytown, Texas, United States
Research SiteRecruiting
Houston, Texas, United States
Research SiteRecruiting
Houston, Texas, United States
Research SiteRecruiting
Mesquite, Texas, United States
Research SiteRecruiting
Tomball, Texas, United States
Research SiteRecruiting
Caba, Argentina
Research SiteRecruiting
Ciudad de Buenos Aires, Argentina
Research SiteRecruiting
Ciudad de Buenos Aires, Argentina
Research SiteRecruiting
Córdoba, Argentina
Research SiteRecruiting
San Isidro, Argentina
Research SiteRecruiting
San Miguel de Tucumán, Argentina
Research SiteRecruiting
Juiz de Fora, Brazil
Research SiteRecruiting
Pelotas, Brazil
Research SiteRecruiting
Porto Alegre, Brazil
Research SiteRecruiting
Porto Alegre, Brazil
Research SiteRecruiting
Salvador, Brazil
Research SiteWithdrawn
São Paulo, Brazil
Research SiteRecruiting
São Paulo, Brazil
Research SiteRecruiting
Haskovo, Bulgaria
Research SiteRecruiting
Pleven, Bulgaria
Research SiteRecruiting
Sofia, Bulgaria
Research SiteRecruiting
Sofia, Bulgaria
Research SiteRecruiting
Sofia, Bulgaria
Research SiteRecruiting
Sofia, Bulgaria
Research SiteNot Yet Recruiting
Niagara Falls, Ontario, Canada
Research SiteNot Yet Recruiting
Ottawa, Ontario, Canada
Research SiteRecruiting
Windsor, Ontario, Canada
Research SiteRecruiting
Trois-Rivières, Quebec, Canada
Research SiteWithdrawn
Providencia, Chile
Research SiteRecruiting
Santiago, Chile
Research SiteRecruiting
Santiago, Chile
Research SiteRecruiting
Temuco, Chile
Research SiteRecruiting
Valdivia, Chile
Research SiteRecruiting
Victoria, Chile
Research SiteRecruiting
Viña del Mar, Chile
Research SiteRecruiting
Beijing, China
Research SiteRecruiting
Beijing, China
Research SiteRecruiting
Changchun, China
Research SiteRecruiting
Changsha, China
Research SiteRecruiting
Guangzhou, China
Research SiteRecruiting
Jiujiang, China
Research SiteNot Yet Recruiting
Kunming, China
Research SiteRecruiting
Linyi, China
Research SiteRecruiting
Nanchong, China
Research SiteRecruiting
Panjin, China
Research SiteRecruiting
Pingxiang, China
Research SiteRecruiting
Shantou, China
Research SiteRecruiting
Xuzhou, China
Research SiteRecruiting
Yangzhou, China
Research SiteRecruiting
Zhengzhou, China
Research SiteWithdrawn
Bad Doberan, Germany
Research SiteRecruiting
Berlin, Germany
Research SiteRecruiting
Hamburg, Germany
Research SiteRecruiting
Sendenhorst, Germany
Research SiteRecruiting
Budapest, Hungary
Research SiteRecruiting
Budapest, Hungary
Research SiteWithdrawn
Budapest, Hungary
Research SiteRecruiting
Debrecen, Hungary
Research SiteRecruiting
Gyula, Hungary
Research SiteRecruiting
Szeged, Hungary
Research SiteRecruiting
Székesfehérvár, Hungary
Research SiteRecruiting
Veszprém, Hungary
Research SiteRecruiting
Aomori, Japan
Research SiteRecruiting
Bunkyō City, Japan
Research SiteRecruiting
Fukuoka, Japan
Research SiteRecruiting
Hamamatsu, Japan
Research SiteRecruiting
Hitachi-Naka, Japan
Research SiteRecruiting
Iizuka-shi, Japan
Research SiteRecruiting
Kawachinagano-shi, Japan
Research SiteRecruiting
Matsuyama, Japan
Research SiteRecruiting
Meguro-ku, Japan
Research SiteRecruiting
Miyazaki, Japan
Research SiteRecruiting
Nagoya, Japan
Research SiteWithdrawn
Okayama, Japan
Research SiteRecruiting
Sagamihara-shi, Japan
Research SiteWithdrawn
Sapporo, Japan
Research SiteRecruiting
Sasebo-shi, Japan
Research SiteRecruiting
Sayama-shi, Japan
Research SiteRecruiting
Yokohama, Japan
Research SiteRecruiting
Chihuahua City, Mexico
Research SiteRecruiting
Estado de México, Mexico
Research SiteNot Yet Recruiting
Guadalajara, Mexico
Research SiteNot Yet Recruiting
Guadalajara, Mexico
Research SiteNot Yet Recruiting
Guadalajara, Mexico
Research SiteNot Yet Recruiting
Gustavo A. Madero, Mexico
Research SiteNot Yet Recruiting
Mexicali, Mexico
Research SiteRecruiting
Mexico City, Mexico
Research SiteRecruiting
Mérida, Mexico
Research SiteNot Yet Recruiting
Monterrey, Mexico
Research SiteWithdrawn
San Luis Potosí City, Mexico
Research SiteRecruiting
Krakow, Poland
Research SiteRecruiting
Krakow, Poland
Research SiteRecruiting
Torun, Poland
Research SiteRecruiting
Warsaw, Poland
Research SiteRecruiting
Wroclaw, Poland
Research SiteRecruiting
Caguas, Puerto Rico
Research SiteWithdrawn
Brackenfell, South Africa
Research SiteRecruiting
Cape Town, South Africa
Research SiteRecruiting
Durban, South Africa
Research SiteRecruiting
Pinelands, South Africa
Research SiteRecruiting
Pretoria, South Africa
Research SiteWithdrawn
Pretoria, South Africa
Research SiteRecruiting
Somerset West, South Africa
Research SiteRecruiting
Barcelona, Spain
Research SiteRecruiting
Barcelona, Spain
Research SiteRecruiting
Barcelona, Spain
Research SiteRecruiting
Málaga, Spain
Research SiteRecruiting
Sabadell, Spain
Research SiteRecruiting
Santiago de Compostela, Spain
Research SiteRecruiting
Valencia, Spain
Research SiteRecruiting
Ivano-Frankivsk, Ukraine
Research SiteRecruiting
Kyiv, Ukraine
Research SiteRecruiting
Kyiv, Ukraine
Research SiteRecruiting
Kyiv, Ukraine
Research SiteRecruiting
Kyiv, Ukraine
Research SiteRecruiting
Kyiv, Ukraine
Research SiteRecruiting
Uzhhorod, Ukraine
Research SiteRecruiting
Vinnytsia, Ukraine
Research SiteRecruiting
Vinnytsia, Ukraine
Research SiteRecruiting
Glasgow, United Kingdom
Research SiteRecruiting
Leeds, United Kingdom
Research SiteRecruiting
Luton, United Kingdom
Research SiteWithdrawn
Staffordshire, United Kingdom
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis · TrialPath